Diabetes technology & therapeutics最新文献

{"title":"Phenolic Preservatives Are Not the Sole Cause of Eosinophilic Infiltration at Infusion Pump Sites.","authors":"Priscila Silva Cunegundes, Kenneth Wood, Li Mao, Ulrike Menkes","doi":"10.1089/dia.2025.0043","DOIUrl":"10.1089/dia.2025.0043","url":null,"abstract":"<p><p><b><i>Background:</i></b> Skin reactions and discomfort associated with insulin infusion pumps limit user adherence. A recent histopathological study by Kalus et al. (DERMIS study) reported increased eosinophilic infiltration and imputed an inflammatory response to an allergen delivered at the catheter tip. This finding might explain the pruritus reported by pump users. As eosinophils migrate to inflammatory foci, primarily due to IL-5 and CCL11, we aimed to evaluate insulin phenolic preservative (IPP) as a potential allergen in vitro and assess tissue eosinophilic infiltration in vivo. <b><i>Methods:</i></b> Histopathological evaluations for eosinophil recruitment were performed over 1 week following IPP infusions in swine tissue. Additional histopathological investigations of eosinophilic infiltration were conducted using three commercial glucose sensors implanted in swine for up to 3 weeks. <b><i>Results:</i></b> Eosinophilic infiltration in the dermis and subcutaneous tissue was observed following saline and IPP infusion and at glucose sensor implantation at all time points examined. In vitro studies revealed IPP eosinophil cytotoxicity. However, neither CCL11 nor IL-5 was detected in any of the tested tissue cells after IPP treatment. <b><i>Conclusion:</i></b> These findings suggest that IPP is not the only triggering allergen, as IPP did not induce eosinophils in vitro, while glucose sensors also indicated increased eosinophilic infiltration. Therefore, factors other than IPP trigger eosinophil recruitment to insulin infusion pump sets.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"577-586"},"PeriodicalIF":6.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Adequacy of Coefficient of Variation and Standard Deviation as Metrics of Glucose Variability in Type 1 Diabetes Based on Data from the GOLD and SILVER Trials.","authors":"Pavel Fatulla, Henrik Imberg, Sofia Sterner Isaksson, Irl B Hirsch, Johan Mårtensson, Hanna Liljebäck, Tim Heise, Marcus Lind","doi":"10.1089/dia.2024.0540","DOIUrl":"10.1089/dia.2024.0540","url":null,"abstract":"<p><p><b><i>Objective:</i></b> Evaluate the adequacy of the coefficient of variation (CV) and standard deviation (SD) as metrics of glucose variability (GV) across mean glucose (MG) levels in individuals with type 1 diabetes. <b><i>Methods:</i></b> Data from the GOLD and SILVER trials were analyzed. Glucose metrics were derived from continuous glucose monitoring (CGM). Generalized estimating equations were used to assess the relationship between SD and MG, considering intraindividual correlations. Nonlinear associations were evaluated using restricted cubic splines, and glucose values outside the CGM detection range (<2.22 mmol/L and >22.2 mmol/L) were handled using a censored Gamma model. <b><i>Results:</i></b> In total, 158 individuals with an MG of 10.6 (SD 1.7) mmol/L were included. The SD of glucose values exhibited a nonlinear relationship with the MG during CGM and self-monitoring of blood glucose (SMBG) (both <i>P</i> < 0.001 vs. linear model). The lack of fit of the constant CV model was most distinct at high glucose levels >12 mmol/L. During SMBG, a 25% reduction in MG from 12 to 9 mmol/L was associated with a 16% (95% confidence interval [CI] 10%-21%) reduction in the SD of glucose values. Similar associations were observed during CGM. This deviation was attributed to the censoring of glucose values outside the detection range. After adjusting for censoring, the lack of fit was resolved. When transitioning from SMBG to CGM, the ordinary CV and SD underestimated the treatment effect on GV by 30% and 27%, respectively, compared to estimates adjusted for censoring. Similarly, ordinary CV underestimated the treatment effect by 11% compared with CV adjusted for the nonlinear SD-MG relationship in the GOLD study. <b><i>Conclusion:</i></b> The SD of glucose values does not increase linearly with the MG during glucose-lowering therapy, suggesting that CV is not an optimal measure of GV. After adjusting for censored glucose values, CV remains reliable. Alternatively, nonlinear SD adjustments relative to MG effectively evaluate glucose-lowering therapies' impact on GV.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"606-612"},"PeriodicalIF":6.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of an Insulin Bolus Calculator on Glycemic Control in Relation to Exercise-A Crossover Randomized Controlled Trial.","authors":"Kenney Fehrenkamp Pedersen, Pernille Rudebeck Mogensen, Mikkel Thor Olsen, Gaspar Letnar, Maria Amlund Kunckel, Ditte Hjorth Laursen, Peter Lommer Kristensen","doi":"10.1177/15209156251364547","DOIUrl":"10.1177/15209156251364547","url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Exercise benefits individuals with type 1 diabetes (T1D) but is often hindered by the risk of hypoglycemia. While guidelines provide strategies to mitigate this risk, adherence to recommendations on exercise remains low. Bolus calculators, such as Hedia Diabetes Assistant (HDA), offer a potential way to address this challenge by integrating exercise-related insulin adjustments into daily routines. This trial evaluates the safety and efficacy of HDA in improving glycemic control during exercise. <b><i>Methods:</i></b> This randomized, controlled crossover pilot study included 20 adults diagnosed with T1D for >1 year using multiple daily insulin injections and HbA1c between 42 and 72 mmol/mol (6.0-8.6%). Participants were randomized to first use either HDA (arm A) or their habitual diabetes management (arm B) before and after performing a 45-min moderate-intensity session on an exercise bike and subsequently crossover. The primary outcome was change in time in range (TIR) over the two 24 h periods. <b><i>Results:</i></b> The mean differences (95% confidence interval [CI]) in TIR and time above range (>10.0 mmol/L) were -2.3% (-13.1%, 8.5%) and 3.93% (-5.7%, 13.5%), respectively, and the median difference in time below range (<3.9 mmol/L) was -0.87% (-2.8%, 0.5%). The incidence rate ratio (95% CI) for total hypoglycemic episodes using HDA was -0.56 (-1.41, 0.29). Safety outcomes revealed fewer adverse events when using HDA. <b><i>Conclusion:</i></b> The HDA insulin bolus calculator with an integrated exercise feature appears safe to use when compared with habitual insulin management in people with T1D during moderate-intensity exercise.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-Guided Cardiac Computer Tomography in Type 1 Diabetes Patients with Low Coronary Artery Calcium Score.","authors":"Peter Wohlfahrt, Michal Pazderník, Natália Marhefková, Robert Roland, Theodor Adla, James Earls, Martin Haluzík, Michal Dubský","doi":"10.1177/15209156251363492","DOIUrl":"10.1177/15209156251363492","url":null,"abstract":"<p><p><b><i>Objective:</i></b> Cardiovascular risk stratification based on traditional risk factors lacks precision at the individual level. While coronary artery calcium (CAC) scoring enhances risk prediction by detecting calcified atherosclerotic plaques, it may underestimate risk in individuals with noncalcified plaques-a pattern common in younger type 1 diabetes (T1D) patients. Understanding the prevalence of noncalcified atherosclerosis in T1D is crucial for developing more effective screening strategies. Therefore, this study aimed to assess the burden of clinically significant atherosclerosis in T1D patients with CAC <100 using artificial intelligence (AI)-guided quantitative coronary computed tomographic angiography (AI-QCT). <b><i>Methods:</i></b> This study enrolled T1D patients aged ≥30 years with disease duration ≥10 years and no manifest or symptomatic atherosclerotic cardiovascular disease (ASCVD). CAC and carotid ultrasound were assessed in all participants. AI-QCT was performed in patients with CAC 0 and at least one plaque in the carotid arteries or those with CAC 1-99. <b><i>Results:</i></b> Among the 167 participants (mean age 52 ± 10 years; 44% women; T1D duration 29 ± 11 years), 93 (56%) had CAC = 0, 46 (28%) had CAC 1-99, 8 (5%) had CAC 100-299, and 20 (12%) had CAC ≥300. AI-QCT was performed in a subset of 52 patients. Only 11 (21%) had no evidence of coronary artery disease. Significant coronary stenosis was identified in 17% of patients, and 30 (73%) presented with at least one high-risk plaque. Compared with CAC-based risk categories, AI-QCT reclassified 58% of patients, and 21% compared with the STENO1 risk categories. There was only fair agreement between AI-QCT and CAC (κ = 0.25), and a slight agreement between AI-QCT and STENO1 risk categories (κ = 0.02). <b><i>Conclusion:</i></b> AI-QCT may reveal subclinical atherosclerotic burden and high-risk features that remain undetected by traditional risk models or CAC. These findings challenge the assumption that a low CAC score equates to a low cardiovascular risk in T1D.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ease of Use of the Reusable DuraTouch Pen Injector in Individuals with Diabetes with and Without Previous Pen Injector Experience: A Handling Study.","authors":"Shahid Akhtar, Anya Sonia Wernersson, Birgitte Berg, Jonathan Comins, Anne-Marie Barkley Jessen, Bastian Gaardsvig Kjeldsen, Sascha Kopic, Niklas Kahr Rasmussen, Elisabeth Rundell, Gitte Ter-Borch, Thomas Sparre","doi":"10.1177/15209156251363465","DOIUrl":"https://doi.org/10.1177/15209156251363465","url":null,"abstract":"<p><p>This single-arm handling study assessed whether the reusable DuraTouch® pen injector is easy to use and easy to learn how to use in adults with type 1 diabetes (T1D) or type 2 diabetes (T2D) with or without prior pen injector experience. Following a 15-min training session, participants were instructed to independently administer a simulated DuraTouch injection. Of the 100 included participants (91% with T2D, 9% with T1D), 50% had prior pen injector experience. Pen injector-naive participants required more training time than pen injector-experienced participants (median time, 11 vs. 9 min, respectively). Overall, 85% of participants found DuraTouch very easy or extremely easy to use (using the Diabetes Pen Experience Measure), and 87% found it easy or very easy to learn how to use (using the Injection Device Experience and Acceptability questionnaire). DuraTouch may be a viable pen injector alternative for individuals with diabetes, irrespective of prior pen injector experience.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Pilot Study Evaluating Meal Timing, Macronutrient Composition, and Faster-Acting Insulin Aspart Versus Insulin Aspart on Postprandial Glycemia with the Medtronic Advanced Hybrid Closed-Loop System.","authors":"Dale J Morrison, Melissa H Lee, Sara Vogrin, Declan Hennessy, Emma Netzer, Hannah M Jones, Lesley Robinson, Carmel E Smart, Natalie Kurtz, Anirban Roy, Benyamin Grosman, David O'Neal","doi":"10.1177/15209156251362500","DOIUrl":"https://doi.org/10.1177/15209156251362500","url":null,"abstract":"<p><p><b><i>Background:</i></b> This study compared postprandial glycemia with faster-acting insulin aspart (FiAsp) versus insulin aspart delivered by advanced hybrid closed loop (AHCL) according to varying meal composition, time of day, and premeal bolus dose estimation in adults with type 1 diabetes. <b><i>Materials and Methods:</i></b> Participants received 11 weeks of insulin aspart and FiAsp in sequence, delivered by the MiniMed™ 780G AHCL algorithm, and within each period ingested 12 standardized meals. Test meals, containing 60 g of carbohydrate but varying by fat and protein content (high fat low protein [HFLP], high fat high protein [HFHP], and low fat low protein [LFLP]), were each eaten in the morning and evening and with a full bolus or 50% reduction. The primary outcome was continuous glucose monitoring time in range (%TIR; 3.9-10.0 mmol/L) 4 h postmeal for FiAsp versus insulin aspart. <b><i>Results:</i></b> Twelve participants (mean [standard deviation or SD] age 48 (13) years; 58% male; HbA1c 6.7 (0.7)%/50 (7) mmol/mol) were recruited. When all meal types, timing, and bolus conditions were combined, FiAsp tended to have greater glucose TIR compared with insulin aspart (mean difference = 5.17% [-0.09, 10.43]; <i>P</i> = 0.054), with differences most apparent for morning meals. Insulin formulation did not impact outcomes with full versus 50% premeal bolus or meal composition. HFLP meals resulted in the greatest TIR, followed by HFHP and lowest for LFLP (83.7% [19.6] vs. 74.7% [26.9] vs. 62.0% [23.1], respectively, mean [SD], <i>P</i> < 0.01). <b><i>Conclusions:</i></b> For adults with type 1 diabetes who are susceptible to morning hyperglycemia, FiAsp delivered by AHCL and higher fat content of meals may help improve postprandial glycemic outcomes. <b><i>Clinical Trial Registration:</i></b> Australian New Zealand Clinical Trials Registry-ACTRN12619001340123.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventing Diabetic Ketoacidosis with Continuous Ketone Monitoring: Insights from a Clinical Research Case.","authors":"Yee Wen Kong, Hanna C Jones, Jennifer Ngan, Jenna Goad, Alicia J Jenkins, Christopher J Nolan, Dale Morrison, Elif I Ekinci, Richard J MacIsaac, Spiros Fourlanos, Stephen Stranks, David N O'Neal","doi":"10.1177/15209156251362494","DOIUrl":"https://doi.org/10.1177/15209156251362494","url":null,"abstract":"<p><p>Delayed identification of impending diabetic ketoacidosis (DKA) often results in hospitalizations. We describe a case where continuous ketone monitor (CKM) use facilitated prompt identification and intervention for impending DKA, avoiding hospitalization. A 55-year-old male (total daily insulin dose of 0.5 units/kg/day; HbA1c 6.9% [51.9 mmol/mol]) with type 1 diabetes using automated insulin delivery (AID) wore a CKM (Abbott) and was educated in responses to ketone information as part of a clinical trial (ACTRN12624000448549). Insulin pump cannula dislodgement resulted in a rapid rise in ketone levels. Initial CKM alarm notification for elevated ketones >1.0 mmol/L prompted initiation of management, including cannula replacement and additional insulin administration. Ketosis resolved following a rise to >3.1 mmol/L without need for hospitalization. He remained asymptomatic throughout. This case highlights the potential for CKM to act as an early warning system to facilitate timely intervention for ketonemia and reduce the risk of DKA and associated hospitalizations.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Evidence of the Effect of Adjunctive Semaglutide on Weight Change, Glycemic Control, and Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes.","authors":"Jonathan Mertens, Hennah T De Winter, Eveline Dirinck, Sven Francque, Christophe De Block","doi":"10.1177/15209156251362497","DOIUrl":"https://doi.org/10.1177/15209156251362497","url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Obesity is increasingly prevalent in type 1 diabetes (T1D), contributing to insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD). While semaglutide has demonstrated weight loss, improved glycemic control, and cardiovascular benefits in type 2 diabetes, its use in T1D remains unapproved. <b><i>Aims and Methods:</i></b> This real-world study evaluates the effects of once-weekly semaglutide in overweight/obese adults with T1D after 12 months of follow-up. Inclusion criteria were stable glycemic control (ΔHbA1c < 0.3%), stable body weight (Δweight < 3%), and consistent total daily insulin requirement (TDI, ΔTDI < 5%) over the preceding year. Changes in weight, total daily insulin dose (TDI), glycated hemoglobin A1c (HbA1c), and metabolic markers, including controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), were assessed at baseline and 12 months. <b><i>Results:</i></b> Among 42 subjects (53% male, age 46 ± 12 years, diabetes duration 28 ± 12 years, HbA1c 7.4 ± 0.8%, body mass index 32.2 ± 4.3 kg/m²), 76.2% had obesity. Eight subjects discontinued treatment, mainly due to gastrointestinal intolerance. Mean relative weight loss was 13.3 ± 11.3% (<i>P</i> < 0.001), with 76.4% attaining ≥5% weight loss and 61.7% attaining ≥10%. Obesity prevalence decreased to 29.4% (<i>P</i> < 0.001). HbA1c decreased by 0.4 ± 0.6% (<i>P</i> < 0.001), with 42% achieving a reduction of ≥0.5%. No significant changes in continuous glucose monitoring-derived parameters were observed in those with available data (<i>n</i> = 28). TDI reduced by 13.6 ± 16.0% (<i>P</i> < 0.001), whereas TDI/kg of body weight remained stable. In 23 subjects with serial hepatic imaging, MASLD prevalence reduced from 82.6% to 30.4% (<i>P</i> < 0.001), CAP decreased by 45 ± 33 decibels/m, and significant fibrosis (based on LSM >8 kPa) declined from 20.6% to 4.5% (<i>P</i> < 0.001). <b><i>Conclusion:</i></b> Semaglutide in T1D was safe and well-tolerated and led to significant weight loss, improved glycemic control, and amelioration of MASLD.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a Specialized Team in Diabetes on Glucometric Parameters and Efficiency Indicators During Hospital Admission in Medical Units.","authors":"Pedro Gil, Judit Amigó, Ángel Ortiz-Zúñiga, Mónica Sánchez, Marcos Dos Santos, Fátima Cuadra, María José Abadias, Cristina Hernández, Rafael Simó, Olga Simó-Servat","doi":"10.1177/15209156251362705","DOIUrl":"https://doi.org/10.1177/15209156251362705","url":null,"abstract":"<p><p>The study aimed to assess the impact of a specialized diabetes team (SDT) on medical units in terms of the improvement of glycemic parameters and hospital efficiency indicators such as length of stay (LOS) and readmissions. For this purpose, a prospective study including 289 patients under standard of care and 149 under the management of SDT was conducted. The SDT comprised two endocrinologists and two nurses specialized in diabetes. Patients under SDT management presented a significant reduction of both hypoglycemia prevalence 8.8% versus 17.6% (<i>P</i> = 0.013) and LOS (12.56 ± 11.94 vs. 16.28 ± 15.54; <i>P</i> = 0.005). In the multivariate analysis, hypoglycemia was independently related to LOS. In addition, the management by SDT resulted in a reduction in readmissions due to acute hyperglycemia at 3 months after the discharge (<i>P</i> = 0.019). We conclude that the management of diabetes by an SDT in medical units is an effective and cost-benefit strategy.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Beyond Accuracy: Clinical Considerations for Personal Continuous Glucose Monitoring Use During Hospitalization.","authors":"Yadi Li, Zheng Wei, Jianlong Zhou","doi":"10.1177/15209156251362492","DOIUrl":"https://doi.org/10.1177/15209156251362492","url":null,"abstract":"","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}